• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

NewCo News: EpiTherapeutics Leveraging Epigenetics Against Cancer

May 6, 2011
By Marie Powers
EpiTherapeutics ApS is a little company with big plans. Last December, the Copenhagen, Denmark-based firm inked its first drug discovery agreement with Abbott, of Abbott Park, Ill., to develop cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Read More

Cytogel Seeks to Impact Pain Management Market

April 28, 2011
By Marie Powers
After nearly a decade of effort, biopharmaceutical development company Cytogel Pharma LLC recently moved its lead candidate – a chemically stabilized analogue of endomorphin (EM) 1 designed to treat acute and chronic pain – into the clinic.
Read More

Akebia Raises $22M to Wrap Up Phase IIb Anemia Studies

April 27, 2011
By Marie Powers
Akebia Therapeutics Inc. raised $22 million in a Series B preferred stock financing that will allow the privately held company to complete two Phase IIb studies for its anemia drug, AKB-6548, and position the program for pivotal studies.
Read More

FDA Reverses, Approves XenoPort's Horizant for RLS

April 8, 2011
By Marie Powers
What a difference a year makes.
Read More

Sunesis Finds New Oncology Partner in $60M Millennium Deal

April 6, 2011
By Marie Powers
Millennium, of Cambridge Mass., has rescued the kinase inhibitor program in oncology at Sunesis Pharmaceuticals Inc. after development partner Biogen Idec exited the oncology market last fall. Millennium, a unit of Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, inked a licensing agreement that covers the development of Sunesis' oral, Phase I-ready selective pan-Raf kinase inhibitor and an additional preclinical kinase inhibitor program with an undisclosed oncology target.
Read More

Biogen Idec, Knopp Launch Phase III Trial for ALS Drug

April 1, 2011
By Marie Powers
Development partners Biogen Idec and privately held Knopp Biosciences LLC have enrolled the first patient in EMPOWER, a multinational Phase III study evaluating the efficacy, safety and pharmacokinetics of the drug candidate dexpramipexole (KNS-760704) in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease.
Read More

IPO Parade Marches on with Insys Therapeutics' $55M filing

March 31, 2011
By Marie Powers
In yet another sign that the biotech industry seems to be tracking the U.S. economy's slow but steady recovery, Insys Therapeutics Inc., of Phoenix, filed with the SEC on Wednesday to raise up to $55 million in an initial public offering (IPO).
Read More

NewCo News: ImmusanT Seeks to Restore Gluten Tolerance with Vaccine

March 23, 2011
By Marie Powers
Privately held ImmusanT Inc. has become the newest entrant in the wide-open race to find a drug therapy for the inherited autoimmune disorder celiac disease. The company established operations this month in Cambridge, Mass., with the goal of developing an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease, which is triggered by foods containing gluten – the main protein in wheat, rye and barley.
Read More

Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders

March 23, 2011
By Marie Powers
Extending a partnership that dates back to 1999, Genfit, of Lille, France, has inked an agreement with Sanofi-Aventis SA, of Paris, to pursue therapies for the treatment of metabolic disorders. (BioWorld International)
Read More

Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders

March 18, 2011
By Marie Powers
Extending a partnership that dates back to 1999, Genfit, of Lille, France, has inked an agreement with Sanofi-Aventis SA, of Paris, to pursue therapies for the treatment of metabolic disorders.
Read More
Previous 1 2 … 161 162 163 164 165 166 167 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe